ATE307594T1 - Anaesthetische zusammensetzungen enthaltend alfaxalon - Google Patents
Anaesthetische zusammensetzungen enthaltend alfaxalonInfo
- Publication number
- ATE307594T1 ATE307594T1 AT01913388T AT01913388T ATE307594T1 AT E307594 T1 ATE307594 T1 AT E307594T1 AT 01913388 T AT01913388 T AT 01913388T AT 01913388 T AT01913388 T AT 01913388T AT E307594 T1 ATE307594 T1 AT E307594T1
- Authority
- AT
- Austria
- Prior art keywords
- alfaxalone
- compositions containing
- anaesthetic compositions
- anaesthetic
- solution
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- DUHUCHOQIDJXAT-OLVMNOGESA-N 3-hydroxy-(3-α,5-α)-Pregnane-11,20-dione Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1=O DUHUCHOQIDJXAT-OLVMNOGESA-N 0.000 title abstract 2
- 229960003305 alfaxalone Drugs 0.000 title abstract 2
- 230000003444 anaesthetic effect Effects 0.000 title abstract 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 2
- 241000282472 Canis lupus familiaris Species 0.000 abstract 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- 241000282326 Felis catus Species 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000008363 phosphate buffer Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPQ6339A AUPQ633900A0 (en) | 2000-03-20 | 2000-03-20 | Anaesthetic composition |
| PCT/AU2001/000307 WO2001070234A1 (en) | 2000-03-20 | 2001-03-20 | Anaesthetic composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE307594T1 true ATE307594T1 (de) | 2005-11-15 |
Family
ID=3820436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01913388T ATE307594T1 (de) | 2000-03-20 | 2001-03-20 | Anaesthetische zusammensetzungen enthaltend alfaxalon |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US7897586B2 (de) |
| EP (1) | EP1265618B1 (de) |
| JP (1) | JP4886145B2 (de) |
| AT (1) | ATE307594T1 (de) |
| AU (1) | AUPQ633900A0 (de) |
| CA (1) | CA2400133C (de) |
| DE (1) | DE60114384T2 (de) |
| WO (1) | WO2001070234A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070166187A1 (en) * | 2006-01-18 | 2007-07-19 | Song Jing F | Stabilization of paricalcitol using chlorobutyl or chlorinated butyl stoppers |
| CA2786762C (en) * | 2010-01-21 | 2017-12-05 | Goodchild Investments Pty Ltd | Anaesthetic formulation |
| AU2013200895C1 (en) * | 2010-01-21 | 2014-02-06 | Drawbridge Pharmaceuticals Pty Ltd | Anaesthetic formulation |
| HRP20200567T1 (hr) | 2011-11-29 | 2020-06-26 | Jurox Pty Ltd | Stabilni injektabilni farmaceutski pripravci koji sadrže 2-hidroksipropil-beta-ciklodekstrin i alfaksalon |
| ES2576077B1 (es) * | 2016-03-04 | 2017-03-24 | Universidad Politécnica De Cartagena | Solución anestesiante y su método de aplicación para el anestesiado, aturdido y sacrificio de peces |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| ES2058503T5 (es) * | 1988-03-29 | 1999-04-16 | Univ Florida | Formulaciones farmaceuticas para uso parenteral. |
| DE69006259T2 (de) * | 1989-05-24 | 1994-06-09 | Innovet Inc | Hypoallergene anästhesierende/hypnotische steroide Arzneizubereitung. |
| WO1993017711A1 (en) | 1992-03-11 | 1993-09-16 | Australian Commercial Research & Development Limited | New cyclodextrins and new formulated drugs |
| US5324718A (en) * | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
| US5472954A (en) * | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
| DE4242919A1 (de) | 1992-12-18 | 1994-06-23 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF |
| FR2733423B1 (fr) * | 1995-04-26 | 1997-06-20 | Virbac Lab | Compositions pulverulentes et solubles dans l'eau et leurs applications |
| TW385248B (en) | 1995-10-27 | 2000-03-21 | Merck & Co Inc | Pharmaceutical compositions for intravenous administration for inhibiting platelet aggregation |
| EP1044016B1 (de) | 1998-01-09 | 2005-03-16 | Novo Nordisk A/S | Stabilisierte insulin-zubereitungen |
| US6123123A (en) * | 1999-08-03 | 2000-09-26 | M. Carder Industries, Incorporated | Non-stretch breakaway hose particularly for fuel dispenser |
-
2000
- 2000-03-20 AU AUPQ6339A patent/AUPQ633900A0/en not_active Abandoned
-
2001
- 2001-03-20 CA CA002400133A patent/CA2400133C/en not_active Expired - Lifetime
- 2001-03-20 DE DE60114384T patent/DE60114384T2/de not_active Expired - Lifetime
- 2001-03-20 EP EP01913388A patent/EP1265618B1/de not_active Expired - Lifetime
- 2001-03-20 JP JP2001568432A patent/JP4886145B2/ja not_active Expired - Lifetime
- 2001-03-20 AT AT01913388T patent/ATE307594T1/de not_active IP Right Cessation
- 2001-03-20 WO PCT/AU2001/000307 patent/WO2001070234A1/en not_active Ceased
- 2001-03-20 US US10/130,573 patent/US7897586B2/en not_active Expired - Fee Related
-
2011
- 2011-02-28 US US13/036,331 patent/US20110152216A1/en not_active Abandoned
-
2012
- 2012-08-23 US US13/592,842 patent/US20120316134A1/en not_active Abandoned
-
2014
- 2014-07-08 US US14/325,485 patent/US9427443B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7897586B2 (en) | 2011-03-01 |
| CA2400133C (en) | 2008-05-06 |
| EP1265618B1 (de) | 2005-10-26 |
| JP4886145B2 (ja) | 2012-02-29 |
| EP1265618A1 (de) | 2002-12-18 |
| DE60114384T2 (de) | 2006-07-06 |
| JP2003527431A (ja) | 2003-09-16 |
| WO2001070234A1 (en) | 2001-09-27 |
| DE60114384D1 (de) | 2005-12-01 |
| EP1265618A4 (de) | 2004-05-19 |
| US20110152216A1 (en) | 2011-06-23 |
| US20140323454A1 (en) | 2014-10-30 |
| CA2400133A1 (en) | 2001-09-27 |
| US20030064961A1 (en) | 2003-04-03 |
| US9427443B2 (en) | 2016-08-30 |
| US20120316134A1 (en) | 2012-12-13 |
| AUPQ633900A0 (en) | 2000-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE324122T1 (de) | Verwendung einer zusammensetzung die einen chelatbildner und eine antimikrobielle verbindung enthaltet zur behandlung von biofilmen | |
| TR200302105T4 (tr) | Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları. | |
| ATE421248T1 (de) | Antiseptische zusammensetzungen und verfahren | |
| DK1117440T3 (da) | Farmaceutiske sammensætninger indeholdende paclitaxel | |
| BR9812562A (pt) | Composição aquosa espessada, processo para limpeza de crostas de cal, e, uso de uma mistura ácida | |
| DK1100344T3 (da) | Chitosanholdige flydende præparater og fremgangsmåder til deres fremstilling og anvendelse | |
| IS7214A (is) | Samsetningar sem samanstanda af sefalósporin efnasambandi og notkun þeirra við meðhöndlun á bakteríusýkingum í köttum og hundum | |
| BR0112393A (pt) | Composições e processos para aperfeiçoamento de absorção oral de agentes antimicrobiais | |
| BR0116691A (pt) | Produto antitranspirante, métodos cosméticos para atingir antitranspiração e/ou benefìcio desodorante e método para a fabricação de uma composição antitranspirante | |
| ES2099687T1 (es) | Cementos de fosfato calcico autofraguables y metodos para prepararlos y usarlos. | |
| BRPI0317696B8 (pt) | composição para branqueamento | |
| ATE362314T1 (de) | Herbizidzusammensetzungen umfassend imidazolinonsäure | |
| CY1106015T1 (el) | Ενα συμπυκνωμενο, υδατοδιαλυτο, κοκκωδες σκευασμα ρυθμιστη της φυτικης αναπτυξης και μεθοδοι χρησης και ιδιου | |
| EP1100522A4 (de) | Verabreichung aktiver wirkstoffe über die lunge | |
| MXPA04006210A (es) | Composiciones acuosas que contienen metronidazole. | |
| CY1110061T1 (el) | Συνθεσεις περιλαμβανοντας ενωσεις μοδαφινιλης | |
| BR0015256A (pt) | Composições farmacêuticas contendo uma droga de antibiótico de fluoroquinolona e uma goma de xantano | |
| ATE282317T1 (de) | Antimikrobielle zusammensetzung zur behandlung von rindermastitis | |
| DK1104289T3 (da) | Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister | |
| BR0313257A (pt) | Composição pesticida granulada | |
| CO2024017342A2 (es) | Composiciones y uso de la tirzepatida | |
| BR9911236A (pt) | Solução e método de limpeza | |
| ATE307594T1 (de) | Anaesthetische zusammensetzungen enthaltend alfaxalon | |
| TR200402070T4 (tr) | Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı | |
| AR245591A1 (es) | Una composicion oral estable, con propiedades antiplaca y antigingivales mejoradas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |